Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earnings

Set Alert for Sales & Earnings

Aspen Hunts For Licensing Opportunities After Intense Consolidation

Aspen Pharmacare is looking to build and augment where it has laid down foundations, after reshaping its operations with numerous significant divestments.

Strategy Sales & Earnings

New CEO Plans ‘Transformation’ For Jubilant Generics

Jubilant Pharmova is planning to transform its generics business with the appointment of a new managing director and CEO, after a difficult period for the unit that saw a tough Q1 amid ongoing difficulties linked to an import alert for its Roorkee manufacturing plant.

Executive Changes Leadership

Newly Independent Euroapi Targets €1bn Revenues In 2022

Euroapi says it will keep a close eye on challenging market conditions in 2022 as it as announced its first set of financial results and forecasts after separating from Sanofi.

Ingredients Sales & Earnings

Earnings Recovery For Nichi-Iko Unlikely Before Full Resumption Of Toyama Shipments

Nichi-Iko still has a long road to recovery ahead as it attempts to get its Toyama plant back on its feet.

Sales & Earnings Strategy

Spluttering US Generics Landscape Shows Signs Of Promise In Q2

High-value launches and an improving broader landscape for generic pricing provided a fillip for some US generics manufacturers in the second quarter, although others disclosed that they were still weathering the storm as the end of the year approaches.

Generic Drugs Commercial

Hyloris On Track To Meet 2024 Target During Half-Year Update

Hyloris CEO Stijn Van Rompay said the firm is on track to meet its target of 30 portfolio products by 2024, delivering a confident Q2 half-year update despite some pushback from the US Food and Drug Administration on its Maxigesic IV compound.

Sales & Earnings Strategy

Mayne Pharma Pursues ‘Aggressive Rationalization’ To Rally Revenue

Mayne’s 2022 results take stock of pivotal changes, with the Australian firm drawing down its generics portfolio as it focuses on the US branded products market. These new priorities come amid a high-value asset sale and a change in CEO.

Strategy Sales & Earnings

Stada Enjoys Robust First Half For Generics And Biosimilars

With generics and biosimilars sales continuing to flow in the first half of 2022, Stada reported healthy top- and bottom-line growth for the first six months of the year, including a 23% rise for its adjusted EBITDA.

Sales & Earnings Strategy

Lannett Comes Out Firing On Insulin Pipeline Prospects

Lannett continued to talk up its prospects of launching numerous low-competition, high-value products in the coming years – as it disclosed another sizeable loss for its 2022/23 financial year.

Biosimilars Clinical Trials
UsernamePublicRestriction

Register